ConductScience.org, home

Gene · 51592

TRIM33: tripartite motif containing 33

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. TRIM33: tripartite motif containing 33. Genes, record 51592. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/51592

On this page

Gene

Symbol
TRIM33
HGNC
Name
tripartite motif containing 33
HGNC
NCBI Gene ID
51592
NCBI Gene
HGNC ID
HGNC:16290
HGNC
Ensembl
ENSG00000197323
NCBI Gene
Aliases
DDH4, ECTO, FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9UPN9E3 ubiquitin-protein ligase TRIM331,1279Ensembl, GeneID, HGNC

Source UniProt

Patents30

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1468057Q9UPN9Espacenet
EP 4650780 A22025-11-197551Q9UPN9Espacenet
EP 4640849 A22025-10-291129Q9UPN9Espacenet
EP 4641201 A22025-10-297559Q9UPN9Espacenet
JP 2025519096 A2025-06-241129Q9UPN9Espacenet
JP 2025517969 A2025-06-127559Q9UPN9Espacenet
JP 2025517970 A2025-06-127551Q9UPN9Espacenet
JP 2024161501 A2024-11-1966Q9UPN9Espacenet
KR 1020240108531 A2024-07-0966Q9UPN9Espacenet
EP 4223770 A22023-08-0916Q9UPN9Espacenet

1 to 10 of 30

See all 30 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants881

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleTRIM33 papersNewest fiscal year
ZIAAR041203Muscle Disease Unit222025
P30CA008748Cancer Center Support Grant202025
ZIAES101074Environmental/genetic Risk Factors and Pathogenesis of Autoimmune Disease172025
P30AR070254Johns Hopkins Rheumatic Diseases Resource-based Core Center (Johns Hopkins RDRCC)162025
P30CA016672Cancer Center Support Grant102025
R01AR073208Autoantibodies define scleroderma subgroups with distinct relationships to cancer92025
ZIAES101081Assessment, Therapy and Prevention Of Autoimmune Disease72025
P30CA072720Cancer Center Support Grant42025
T32AR050942Training Program in Adult and Pediatric Rheumatology42025
ZIADE000704Clinical and Mechanistic Investigations of Salivary Gland Dysfunction42025

1 to 10 of 881Source NIH's project files

See all 881 nih grants

Papers2,289

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Age-dependent myositis-specific autoantibody profiles and CD8+ T-cell signatures in juvenile dermatomyositis.Immunol Med202642808692PubTator, text miningPubMed
Transcriptional intermediary factor 1 gamma-based multitarget gene therapeutic strategy for triple-negative breast cancer.Signal Transduct Target Ther202642805968PubTator, text miningPubMed
The TIF-1γ autoantigen in patients with dermatomyositis and thyroid cancer: from case series to preliminary mechanistic exploration.Front Immunol202642774280PubTator, text miningPubMed
Catching up with calcinosis: analysis of clinical characteristics, myositis-specific autoantibodies, and response to therapy in juvenile dermatomyositis.Clin Exp Rheumatol202642752384PubTator, text miningPubMed
Multicenter Clinical Comparison Between Anti-NXP2 and Anti-TIF1-γ Antibody-Positive Myositis, and Analysis of the Clinical Significance of Anti-NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies.
J Dermatol202642750350PubTator, text miningPubMed
Upadacitinib for refractory cutaneous disease in a patient with tif1γ-positive dermatomyositis.An Bras Dermatol202642696844PubTator, text miningPubMed
Clinical characteristics, organ damage and survival in idiopathic inflammatory myopathies: a long-term retrospective cohort study.Rheumatol Int202642667319PubTator, text miningPubMed
A five-factor risk-stratification model for cancer-associated myositis in idiopathic inflammatory myopathies and stage-specific survival analysis: a multicentre Japanese MYKO cohort study.Front Immunol202642643601PubTator, text miningPubMed
Proteomic Signatures and an Injury-Stress Endotype in Myositis-Associated Interstitial Lung Disease.medRxiv202642620435PubTator, text miningPubMed
TIF1γ holds the line against regulatory T cell plasticity.Nat Immunol202642601472PubTator, text miningPubMed

1 to 10 of 2,289

See all 2,289 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/51592

GET https://conductscience.org/api/genes/v1/51592/patents?page=2